Travere Therapeutics (NASDAQ: TVTX) reported Q2 EPS of ($0.65), $0.14 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $54.12 million versus the consensus estimate of $50.4 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.